STStephen Tong

Stephen Tong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen Tong has a total of 573 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidural in Labour and Obstetric Anal Sphincter Injury Risk: A Systematic Review and Meta‐Analysis

    by Danica Idzes, Jessica Atkinson, Hannah Gordon, Stephen Tong, Anna Middleton, Manarangi De Silva, Susan P. Walker, Roxanne Hastie, Anthea Lindquist

    Background: Perineal injury during childbirth is common. The most severe injuries involve damage to the anal sphincter (obstetric anal sphincter injuries). Epidural analgesia provides effective labour pain relief but its impact on the risk of obstetric anal sphincter injury is unclear. Objective: To determine the association between epidural analgesia and the likelihood of obstetric anal sphincter injuries. Search Strategy: Ovid MEDLINE, Ovid EMBASE, PubMed, CINAHL and Web of Science were searched from database inception to October 18, 2025, using key words relating to epidural, perineal trauma and labour. Selection Criteria: Randomised trials and observational studies (cohort, case–control, and cross‐sectional studies) were included. Data Collection and Analysis: Studies reporting the same outcomes were pooled, and odds ratios with 95% confidence intervals were calculated using a random effects meta‐analysis. Main Results: From 24 977 identified studies, 86 were included ( N = 9 826 330 women). Pooled adjusted analyses showed epidural use in labour was associated with a 15% reduced likelihood of obstetric anal sphincter injury in the overall population ( n = 9 302 188; aOR 0.85 [95% CI 0.80–0.91]). Among nulliparous women, there was a 23% reduced likelihood of obstetric anal sphincter injury ( n = 1 083 923; aOR 0.77 [95% CI 0.71–0.83]). Conclusion: After pooling effect measures that corrected for important clinical confounders, our meta‐analysis suggests that epidural use in labour may reduce the likelihood of obstetric anal sphincter injuries among nulliparous women. While our findings must be interpreted within the limitations of observational data, they provide valuable evidence to guide clinical practice and highlight the need for more high‐quality studies to establish causality. Trial Registration: PROSPERO Registration CRD42023412771, 09 April 2023 https://www.crd.york.ac.uk/PROSPERO/view/CRD42023412771

  • Open Access

    Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population‐Based Cohort Study

    by Jessica A. Atkinson, Richard J. Hiscock, Anna Forsythe, Hannah G. Gordon, Jenny Myers, Susan P. Walker, Beverley J. Vollenhoven, Stephen Tong, Roxanne M. Hastie, Anthea C. Lindquist

    Objective: To investigate whether periconceptual use of progesterone is associated with an altered risk of new‐onset hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, or superimposed preeclampsia). Design: Population‐based cohort study using statewide pregnancy and birth data from Victoria, Australia, linked with hospital and medication prescribing data. Setting: Victoria, Australia (2009–2020). Population: Nulliparous women who gave birth between 2009 and 2020 in Victoria, Australia. Women with missing delivery dates, medicine dispensation dates, or who were exposed to progesterone in the second or third trimester were excluded. Methods: We compared nulliparous women exposed to progesterone in the periconceptual period (6 weeks preconception until the end of the first trimester) with those not exposed to progesterone. Inverse probability‐weighted regression adjustment was used to control for confounding factors and investigate the effect of progesterone on the risk of preeclampsia (including superimposed preeclampsia) and gestational hypertension. Main Outcome Measures: Development of preeclampsia or gestational hypertension. Results: Among 386 475 pregnancies, 5657 (1.5%) women used progesterone in the periconceptual period. Progesterone use was associated with a statistically significant reduction in the risk of any new onset hypertensive disorders of pregnancy (adjusted risk ratio [aRR] 0.81 [95% confidence interval [CI] 0.67, 0.98]; adjusted risk difference [aRD] −1.72% [95% CI −3.21%, −0.24%]). Investigating type of hypertension, we found progesterone use was associated with a 1.69% absolute reduced risk of gestational hypertension (aRR 0.60 [95% CI 0.43, 0.83]; aRD −1.69% [95% CI −2.52%, −0.86%]) but no significant change was observed for preeclampsia (aRR 0.97 [95% CI 0.75, 1.25]; aRD −0.13% [95% CI −1.49%, 1.23%]). Restricting our analyses to pregnancies conceived via assisted reproductive technology only, we found similar results, with a statistically significant reduction in the risk of gestational hypertension (aRR 0.80 [95% CI 0.67, 0.95]; aRD −1.02% [95% CI −1.73%, −0.30%]) but not preeclampsia (aRR 0.96 [95% CI 0.83, 1.11]; aRD −0.25% [95% CI −1.23%, 0.72%]). Conclusions: Among 386 475 nulliparous women, we found periconceptual progesterone use to be associated with a statistically significant reduction in the risk of gestational hypertension, but not preeclampsia. However, these findings are unlikely to be clinically meaningful.

  • Open Access

    Can metformin prolong pregnancy in preterm pre-eclampsia? Study protocol for a Nordic multicentre randomised placebo-controlled trial (PI4)

    by Pia Gudmundsson, Catherine Anne Cluver, Anna Sandström, Linda Lindström, Simon Timpka, Susanne Hesselman, Caroline Lilliecreutz, Sophia Brismar Wendel, Emma Von Wowern, Karolina Linden, et al.

    Pre-eclampsia affects 2–8% of all pregnancies and remains a leading cause of maternal and perinatal morbidity and mortality. A randomised trial in South Africa suggested metformin used to treat preterm pre-eclampsia (26–32 weeks’ gestation) may prolong pregnancy by 7 days compared with standard care. However, this finding was borderline significant and requires validation in higher-resource settings and in diverse populations. Here, we present a Nordic multicentre trial protocol designed to evaluate whether extended-release metformin can prolong gestation in women with preterm pre-eclampsia. Pre-eclampsia Intervention 4 trial is a phase III, double-blind, multicentre randomised controlled trial conducted in Sweden, Norway and Finland aiming to investigate whether metformin can prolong gestation in preterm pre-eclampsia. A total of 294 women between 22+0 and 33+6 weeks of gestation with pre-eclampsia and planned to undergo expectant management will be enrolled. Participants are randomised to receive one gram of extended-release metformin or matching placebo three times daily. The primary outcome is prolongation of gestation defined as time from randomisation to birth. Secondary outcomes include length of neonatal hospital stay and neonatal birth weight. Adverse events will be reported in line with current clinical trial guidelines. All efficacy analyses will be conducted according to the intention-to-treat principle. The trial is conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonisation. The protocol, including amendments, was approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency in accordance with national legislation, and authorised for Finland and Norway through the Clinical Trials Information System in accordance with the EU Clinical Trials Regulation. Results will be disseminated at international conferences and published in peer-reviewed journals and communicated via popular science outlets, media, patient organisations and the trial website: https://www.preeclampsiaresearch.com/pi-trials. NCT06033131.

  • Open Access

    Association Between Proteinuria and Pregnancy Outcomes in Women With Preterm Pre‐Eclampsia Undergoing Expectant Management: Secondary Analysis of Two Randomised Trials

    by Amy van Rooyen, Lina Bergman, Henrik Imberg, Denise Sproul, Susan P. Walker, Stephen Tong, Catherine A. Cluver

    Objective: Evaluate whether proteinuria levels, in women undergoing expectant management for pre‐eclampsia, are associated with pregnancy latency and adverse outcomes. Design: Secondary analysis of data from two randomised trials. Setting: Tygerberg Hospital, Cape Town, South Africa. Population: Women undergoing expectant management for pre‐eclampsia diagnosed between 26 and 32 weeks. Methods: Latency was analysed using parametric time‐to‐event methods to estimate increases. Composite outcomes were assessed using Poisson regression. Main Outcome Measures: Pregnancy latency Composite adverse maternal or perinatal outcomes. Results: Two hundred and ninety‐one women were included. Women with < 3 g/24 h had a median prolongation of 15.3 days (interquartile range (IQR) 4.3 to 25.6), compared to 10.0 days (IQR 5.0 to 19.6) with proteinuria between 3 to 5 g/24 h; and 4.9 days (IQR 3.8 to 11.7) for those with ≥ 5 g/24 h. Increasing levels were also associated with increases in subsequent adverse composite maternal outcomes: 8.8% of women with < 3 g/24 h experienced maternal complications, compared to 16.1% with 3 to 5 g/24 h, and 27.9% with ≥ 5 g/24 h. There was no association with composite perinatal adverse outcomes. The sFlt‐1/PIGF ratio performed slightly better in predicting latency (area under the receiver operating characteristic curve (AUC) 0.78 vs. 0.67) but similarly in predicting adverse composite maternal outcomes (AUC 0.67 vs. 0.64). Both had poor performance for predicting composite adverse perinatal outcomes (AUC 0.61 vs. 0.56). Conclusion: Levels of proteinuria strongly correlate with pregnancy latency and adverse maternal outcomes, but not perinatal outcomes, in women with pre‐eclampsia undergoing expectant management. They perform similarly to angiogenic markers. Proteinuria levels may confer useful prognostic information to assist clinical decision‐making.

  • Open Access

    Identifying novel prodromal symptoms of eclampsia: A two-country, case-control study

    by Roxanne Hastie, Farhatulain Ahmed, Parinaz Mehdipour, Bernard Yan, Susan P. Walker, Jacqui Visser, Anam Bashir, Lyle Gurrin, Anthea Lindquist, Jessica A. Atkinson, et al.

    Background: Magnesium sulphate halves the risk of eclampsia. There is no consensus on who to give magnesium sulphate prophylaxis because clinical tools are poor at identifying those at risk. Known prodromal symptoms such as headache, visual disturbance, or epigastric pain have modest associations with eclampsia. We set out to identify new prodromal symptoms of eclampsia. Methods and findings: This case-control study prospectively recruited participants in South Africa and Pakistan who had eclampsia, preeclampsia, or normotensive pregnancies. We asked whether they experienced 20 neurological symptoms, within 7 days of the seizure for those who had eclampsia. The primary analysis was the likelihood of symptoms occurring before eclampsia, compared to being present with preeclampsia. 341 participants were recruited with eclampsia, 1,355 with preeclampsia and 389 with normotensive pregnancies. When comparing symptoms among those who had eclampsia versus preeclampsia, the odds ratios (OR) were 2.56 (95% confidence interval (CI) [1.81,3.62]; p < 0.001) for headache, 5.73 (95% CI [4.44,7.39]; p < 0.001) for visual disturbances and 2.25 (95% CI [1.76,2.89]; p < 0.001) for epigastric pain. We identified 10 symptoms with odds ratios over 10 for eclampsia. Odds ratios were 42.03 (95% CI [23.66,74.68]; p < 0.001) for twitching/jerking limbs (30.5% eclampsia versus 1% preeclampsia); 36.00 (95% CI [18.34,70.65]; p < 0.001) for affected hearing (21.1% versus 0.7%)’ 33.60 (95% CI [21.39,52.78]; p < 0.001) for affected mind state (38.7% versus 1.8%); 33.12 (95% CI [19.46, 54.37]; p < 0.001) for impaired speech; 23.71 (95% CI [16.49,34.10]; p < 0.001) for feelings of doom; 26.59 (95% CI [7.82,90.41]; p < 0.001) for severe vertigo; 20.52 (95% CI [14.22,29.63]; p < 0.001) for confusion; 18.16 (95% CI [10.76,30.66]; p < 0.001) for jitters; 15.18 (95% CI [11.34,20.33]; p < 0.001) for difficulty concentrating; and 10.49 (95% CI [6.76,16.27]; p < 0.001) for weakness/paralysis. These symptoms were rare among normotensive pregnancies. Only 2.4% of women with eclampsia did not experience any prodromal symptoms. This study is limited by the fact that we asked about prodromal symptoms after the seizure happened, and the potential for recall bias. Conclusions: Ten prodromal symptoms exhibit far stronger associations with eclampsia than headache, visual disturbances, or epigastric pain. Eclampsia is uncommon without any prodromal symptoms. It may be useful to screen these symptoms among women with preeclampsia as part of clinical history taking to guide management. They could help direct magnesium sulphate prophylaxis to those with a higher risk of eclampsia.


  • Open Access

    Perinatal outcomes following periconceptual steroid exposure: a population-wide cohort study

    by Anthea C Lindquist, Anna Forsythe, Richard Hiscock, Stephen Tong, Susan Walker, Amber Kennedy, Natasha Pritchard, Elizabeth McCarthy, Hannah Gordon, Jessica Atkinson, et al.

    Importance: Glucocorticoid steroids are increasingly prescribed during the periconceptual period with the hypothesis that they reduce intrauterine inflammation and improve pregnancy rates. There is no robust evidence to support this practice, and the potential harm has not been well characterised. Objective: To examine the risk of adverse perinatal outcomes associated with non-medically indicated glucocorticoid steroid use during the periconceptual period. Design: Population-wide linked retrospective cohort study. Setting: Victoria, Australia. Participants: After excluding women with medical indications for steroid use (autoimmune disease, chronic asthma and previous organ transplant), our total cohort included 805,353 births between 2009 and 2021. Exposure: Prescriptions of glucocorticoid steroids dispensed during the periconceptual period (12 weeks prior to conception – end of first trimester). Main Outcome(s) and Measure(s): Four primary outcomes were examined – spontaneous preterm birth before 37 completed weeks’ gestation, small for gestational age (<10th birthweight centile), major congenital abnormality and perinatal mortality. A doubly robust inverse probability weighted regression adjustment model was used to estimate the association between glucocorticoid steroid exposure and outcomes and presented as adjusted relative risks (aRR) with corresponding 95% confidence intervals (95% CI). Results: There were 12,301 (1.5%) pregnancies exposed to glucocorticoid steroids during the periconceptual period and 793,052 unexposed. Among the steroid-exposed cohort, major congenital abnormalities occurred in 4.5% of pregnancies, compared with 3.5% among those unexposed to steroids. This resulted in a 23% increased risk of major congenital abnormality (aRR 1.23, 95%CI 1.13-1.34). There were no significant associations between steroid exposure and spontaneous preterm birth (2.4 vs 2.5%; aRR 1.05, 95%CI 0.93-1.19), small for gestational age neonates (9.4 vs 9.3%; aRR 1.02, 95%CI 0.97-1.07) or perinatal mortality (0.5 vs 0.7%; aRR 1.05, 95%CI 0.87-1.26). Conclusions and Relevance: In our cohort, periconceptual steroid exposure was associated with an increased risk of major congenital abnormality. In the absence of clear clinical indications, avoiding the prescription of periconceptual steroids is critically important. KEY POINTS: Question: What are the risks of adverse perinatal outcomes among patients prescribed glucocorticoid steroids during the periconceptual period? Findings: Periconceptual steroid use is associated with an increased risk of major congenital abnormality. Meaning: In the absence of an indication, periconceptual steroid use does not have clear evidence of benefit, there is now also evidence of significant harm and this practice should not be recommended.

  • Open Access

    Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial

    by Catherine Anne Cluver, Jacquline Thake, Tasleem Hassim, Anriette van Greunen, Samantha Budhram, Karusha Knipe, Eric Decloedt, Lucy Brink, Eduard Langenegger, Lina Bergman, et al.

    Introduction: Pre-eclampsia and fetal growth restriction are leading causes of perinatal morbidity and mortality. A therapy that enhances maternal vascular function and promotes vasodilation to increase placental perfusion could treat both conditions. Tissue kallikrein-1 is an endogenous enzyme that releases bradykinin to activate the bradykinin 2 receptor on endothelial cells. This induces potent vasodilation and pro-angiogenic, anti-oxidant and anti-inflammatory effects. DM199 is a recombinant form of tissue kallikrein which can be administered intravenously or subcutaneously. Clinical trials in non-pregnant populations have demonstrated its safety. Being a protein, it is unlikely to cross the placenta. This protocol describes an early-phase trial for DM199 for pre-eclampsia and fetal growth restriction. Methods and analysis: This phase IB/IIA open-label trial at Tygerberg Hospital, Western Cape Province, South Africa, will determine the safety and effective dose of DM199 for pre-eclampsia and/or fetal growth restriction. The trial consists of two parts. Part 1 will be an ascending dose finding study, treating women with pre-eclampsia and severe hypertension who are for planned birth within 72 hours. This will search for doses that safely lower blood pressure (n=3/dose, recruiting up to 42 participants). Part 2 is a safety and efficacy study of three cohorts of pregnant women (n=30/cohort): (1) with pre-eclampsia and severe hypertension requiring delivery within 72 hours, (2) with preterm pre-eclampsia (<33 weeks’ gestation) undergoing expectant management and (3) with preterm fetal growth restriction. Primary outcomes will include adverse events and umbilical cord concentrations of DM199. DM199 pharmacokinetics will be described and exploratory outcomes assessed to evaluate preliminary evidence of efficacy. Ethics and dissemination: The trial has ethical approval (Health Research Ethics Committee, Stellenbosch University, Protocol number M24/04/009) and is registered (Pan African Clinical Trial Registry, PACTR202404895013782) and approved by the South African Health Products Regulatory Authority (20240801). Data will be presented at international conferences and published in peer-reviewed journals.


  • Top Cited Papers
    Open Access

    The human placenta and its role in reproductive outcomes revisited

    by Irving L. M. H. Aye, Stephen Tong, D. Stephen Charnock-Jones, Gordon C. S. Smith

    The placenta performs many key tasks that are essential for the healthy growth and development of the human fetus. Placental dysfunction has multiple manifestations, but they share the common property of lacking a mechanistic understanding of etiology. The clinical consequences of placental dysfunction are a major determinant of the global burden of disease. Currently, the primary clinical method for assessing placental function is ultrasonic Doppler flow velocimetry of the umbilical and uterine arteries. More recently, some biomarkers have emerged that can predict or diagnose placentally related complications of pregnancy. However, methods for identifying and characterizing placental dysfunction have developed relatively little over the last 20 years and perform poorly, and there remains an absence of disease-modifying therapies targeted at the placenta. Understanding disease mechanisms is made more difficult due to the profound differences in pregnancy and placentation comparing humans and the most commonly used laboratory animals, limiting the utility of animal models. The use of omics methods in human samples may yield progress: omics analyses of maternal blood show promise in identifying better predictors of disease, and single-cell analyses, including spatial omics of healthy and abnormal placentas, could identify therapeutic targets. Limitations in cellular models of the placenta have been significantly overcome in the last 5 to 10 years by the development of human cell models, including human trophoblast stem cells and organoids, and the use of these model systems may allow hypothesis testing experiments in a more clinically relevant context than animal models or immortalized cell lines.


  • Open Access

    Hypertensive disorders of pregnancy and childhood neurodevelopment: A systematic review and meta-analysis

    by Jessica A. Atkinson, Hannah G. Gordon, Stephen Tong, Susan P. Walker, Parinaz Mehdipour, Anthea C. Lindquist, Roxanne M. Hastie

    Background: Hypertensive disorders of pregnancy may be associated with an increased risk of adverse neurodevelopmental outcomes for the child, though no recent comprehensive meta-analyses exist. The aim of this study was to conduct a systematic review and meta-analysis examining the association between hypertensive disorders of pregnancy and child neurodevelopmental disabilities, intelligence, and educational outcomes. Methods and findings: A search was conducted of MEDLINE, CINAHL, Web of Science, and PsycINFO databases from inception until 18 September 2024. Reference lists of included papers were also screened. Observational studies and secondary analyses of randomized trials reporting neurodevelopmental, cognitive, or educational outcomes for children born following hypertensive disorders of pregnancy against a reference population (unaffected pregnancies) were included. Two reviewers independently screened records, extracted data, and assessed quality of studies using Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Studies reporting similar outcomes were pooled using a random-effects meta-analysis model. Outcomes included autism, attention-deficit/hyperactivity disorder, cerebral palsy, global developmental delay, intellectual disability, intelligence quotient, and educational attainment. Results were reported as odds ratios (OR) or mean difference (MD) with corresponding 95% confidence intervals (CI). After screening 13,419 records, 121 studies reporting outcomes of 29,649,667 offspring were included. We included 85 cohort studies, 30 case-control studies, four cross-sectional studies, and two secondary analyses of randomized trials. Compared with unaffected pregnancies, hypertensive disorders of pregnancy were associated with an increased unadjusted likelihood of autism spectrum disorder (OR 1.65 (95% CI [1.49,1.83]); p < 0.001; n = 26,727,500), attention-deficit/hyperactivity disorder (OR 1.27 (95% CI [1.21,1.33]); p < 0.001; n = 12,987,737), intellectual disability (OR 1.77 (95% CI [1.31,2.38]); p < 0.001; n = 10,718,504), global developmental delay (OR 1.77 (95% CI [1.21,2.59]); p < 0.001; n = 2,961,195), and reduced mean intelligence (MD −2.20 95% CI [−3.35,-1.06]); p < 0.001; n = 1,150,664). Associations between hypertension and autism spectrum disorder and global developmental delay were no longer significant after adjusting for gestational age and birthweight. Results for intelligence quotient remained significant when adjusting for birthweight, but not gestational age. Adjusted analyses for attention-deficit/hyperactivity disorder and intellectual disability could not be performed due to a lack of suitable studies. In sensitivity analyses, results were unchanged after exclusion of papers at high risk of bias. This study is limited by a lack of constituent papers which adjusted for confounding and mediating factors, a high amount of heterogeneity among included studies, and possible publication bias for some outcomes. Conclusions: Hypertensive disorders of pregnancy are potentially associated with adverse neurodevelopmental and cognitive outcomes among affected offspring. While the mechanisms driving these associations are not clear, these results highlight a group of children that will benefit from early intervention and support to improve their neurodevelopmental outcomes.


  • Open Access

    The Fetal Region-specific Optimized Growth Standard (FROGS)—A fetal and birthweight centile calculator validated in a national population

    by Natasha L. Pritchard, Stephen Tong, Teresa MacDonald, Elizabeth McCarthy, Lisa Hui, Michael Bethune, Hannah G. Gordon, Roxanne Hastie, Emerson Keenan, Michael Permezel, et al.

    Background: There is no universally agreed upon obstetric growth standard for use during pregnancy. We aimed to design a simple novel growth standard, which incorporates key beneficial features identified in prior research. Methods and findings: We developed the Fetal Region-specific Optimized Growth Standard (FROGS), then validated it following International Federation of Gynaecology and Obstetrics (FIGO) guidelines. FROGS follows the shape of the fetal (ultrasound-based) Hadlock curve. It is region-specific; allowing adjustment for the mean birthweight and standard deviation of babies born at term in the local population where it will be applied. It provides an exact centile for each gestational day (rather than rounding off by weeks) and is optionally adjustable for fetal sex. Further, FROGS provides an ‘estimate range’ for the estimated fetal weight centile, assuming a 10% ultrasound measurement error. Following development, we validated FROGS in a retrospective cohort study by comparing its ability to identify small babies with an increased risk of adverse perinatal outcomes to four charts in current use: (1) population birthweight chart (Australian Institute of Health and Welfare, AIHW chart); (2) Hadlock’s 1991 fetal chart; (3) Mikolajczyk’s global fetal and birthweight centile chart; and (4) INTERGROWTH-21st fetal growth standards. To do this, we identified infants classified as small for gestational age (<10th centile) by each chart. We then identified non-overlapping <10th centile populations, i.e., infants classified as small by one chart, but not another. We compared rates of stillbirth and adverse perinatal outcomes between the non-overlapping populations. All charts except INTERGROWTH classified similar proportions of infants as <10th centile (10.4% FROGS, 9.3% AIHW, 11.1% Hadlock, 10.9% global, 4.4% INTERGROWTH). Of the three charts that classified similar proportions as <10th centile, infants classified by FROGS were at the highest risk of adverse perinatal outcomes. The infants classified as <10th centile by only FROGS had significantly increased relative risk (RR) of stillbirth, compared to the infants classified as <10th centile by only AIHW (RR 13.1, 95% CI 6.5–26.5), only Hadlock (RR 2.1, 95% CI 1.28–3.56) or only the global chart (RR 1.54, 95% CI 1.00–2.37). The FROGS chart outperformed these three charts in identifying infants at risk of other adverse perinatal outcomes associated with being small for gestational age, such as neonatal intensive care admission, Apgar scores <7 at 5 min, and operative (instrumental) vaginal birth for suspected fetal compromise. The cohort of infants classified as small for gestational age by INTERGROWTH was, in size and risk, closer to the cohort classified as <3rd centile by FROGS (3.4% of infants <3rd). This study is limited in that it retrospectively assesses birthweight, which may have different implications to a prospective evaluation of estimated fetal weight. Conclusions: Compared to currently used charts, the Fetal Region-specific Optimized Growth Standard outperforms existing charts that classify a similar proportion of infants as small for gestational age in identifying small infants at increased risk of stillbirth and other serious perinatal outcomes. The FROGS centile algorithm is simple and transparent. It has the potential to be adapted to other local populations, or applied to clinical and research settings globally.